Codexis Q2 Earnings Call Highlights

Impact · against what's priced in

Codexis shows concrete progress in commercializing its ECO Synthesis platform through GMP facility investment and CDMO negotiations. The combination of a $25 million capital injection for manufacturing and a narrowed net loss improves the company's operational trajectory.

CDXS+0.40

No priced-in read yet

In context

The company is taking a major step toward commercial scale by investing $25 million in a GMP facility and entering commercial negotiations with a CDMO partner, while successfully narrowing its quarterly net loss to $12 million.

Read from the article alone

• guidance
• biotech
• earnings
• CDXS
• biocatalysis
• cdmo
• drug development
• enzymes
• manufacturing
• sirna

Search tags